Reply to Eberlein et al.

length of stay and increased resource utilization was reported [6]. Thus, it would be helpful, if more details on post-transplant complications between groups could be provided. The survival data, which are limited to an unadjusted Kaplan–Meier survival analysis comparing conventional with lobar LTx, make it difficult to interpret the results in context. The lobar LTx group consisted predominantly of patients with cystic fibrosis, who in general have the most favourable long-term survival. It would be informative if the authors could show analysis within the same diagnostic groups (i.e. cystic fibrosis). Furthermore, providing a multivariate Cox proportional hazard model adjusted for important confounders would strengthen the assessment of clinical outcomes. We wish to conclude by thanking and congratulating Inci et al. on their important study on bilateral lobar LTx allowing life-saving transplants in ‘short’ recipients, who otherwise might not be able to receive an appropriately sized allograft in a timely way. REFERENCES